For sure, the CYDY MC is a rough place to be currently. As we are all hoping for more accurate and higher (at least the longs here) value to be reflected in the PPS. So many variables right now, it's may be an impossible question to answer accurately, even based on historical BO deals due to Leronlimab perhaps treading unknown territory as such a wide-use platform molecule. Hopefully if a buyout does happen in the next 6 months, it's not based on the current MC....but rather on the EV plus future milestone developments. (unless the MC drastically goes up within the next 6 months of course :-} Thanks again for your input.